Extranuclear signaling by estrogen: Role in breast cancer progression and metastasis

V. Cortez, M. Mann, Darrell W Brann, R. K. Vadlamudi

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The estrogen receptor (ERα) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERα positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERα extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERα is detected in a subset of breast tumors and expression of extranuclear components ERα is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERα extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERα positive metastasis. In this review, we summarize the results of recent research into the role of ERα mediated extranuclear actions in breast tumorigenesis and metastasis.

Original languageEnglish (US)
Pages (from-to)575-583
Number of pages9
JournalMinerva Ginecologica
Volume62
Issue number6
StatePublished - Dec 1 2010

Fingerprint

Estrogen Receptors
Estrogens
Breast Neoplasms
Neoplasm Metastasis
Neoplasms
Cytoskeleton
Action Potentials
Cell Survival
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Breast
Phosphotransferases
Therapeutics
Cell Proliferation
Cell Membrane
Research

Keywords

  • Breast neoplasms
  • Estrogens
  • Neoplasm metastasis

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Extranuclear signaling by estrogen : Role in breast cancer progression and metastasis. / Cortez, V.; Mann, M.; Brann, Darrell W; Vadlamudi, R. K.

In: Minerva Ginecologica, Vol. 62, No. 6, 01.12.2010, p. 575-583.

Research output: Contribution to journalReview article

Cortez, V. ; Mann, M. ; Brann, Darrell W ; Vadlamudi, R. K. / Extranuclear signaling by estrogen : Role in breast cancer progression and metastasis. In: Minerva Ginecologica. 2010 ; Vol. 62, No. 6. pp. 575-583.
@article{a5b116f8e47643a6909155207045bdd6,
title = "Extranuclear signaling by estrogen: Role in breast cancer progression and metastasis",
abstract = "The estrogen receptor (ERα) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERα positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERα extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERα is detected in a subset of breast tumors and expression of extranuclear components ERα is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERα extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERα positive metastasis. In this review, we summarize the results of recent research into the role of ERα mediated extranuclear actions in breast tumorigenesis and metastasis.",
keywords = "Breast neoplasms, Estrogens, Neoplasm metastasis",
author = "V. Cortez and M. Mann and Brann, {Darrell W} and Vadlamudi, {R. K.}",
year = "2010",
month = "12",
day = "1",
language = "English (US)",
volume = "62",
pages = "575--583",
journal = "Minerva Ginecologica",
issn = "0026-4784",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Extranuclear signaling by estrogen

T2 - Role in breast cancer progression and metastasis

AU - Cortez, V.

AU - Mann, M.

AU - Brann, Darrell W

AU - Vadlamudi, R. K.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The estrogen receptor (ERα) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERα positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERα extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERα is detected in a subset of breast tumors and expression of extranuclear components ERα is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERα extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERα positive metastasis. In this review, we summarize the results of recent research into the role of ERα mediated extranuclear actions in breast tumorigenesis and metastasis.

AB - The estrogen receptor (ERα) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERα positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERα extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERα is detected in a subset of breast tumors and expression of extranuclear components ERα is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERα extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERα positive metastasis. In this review, we summarize the results of recent research into the role of ERα mediated extranuclear actions in breast tumorigenesis and metastasis.

KW - Breast neoplasms

KW - Estrogens

KW - Neoplasm metastasis

UR - http://www.scopus.com/inward/record.url?scp=79952234041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952234041&partnerID=8YFLogxK

M3 - Review article

C2 - 21079578

AN - SCOPUS:79952234041

VL - 62

SP - 575

EP - 583

JO - Minerva Ginecologica

JF - Minerva Ginecologica

SN - 0026-4784

IS - 6

ER -